Immunai Expands Oncology Collaboration, Extending AI-Driven Biomarker and Clinical Insights Through 2027

This agreement marks the third expansion of its collaboration with AstraZeneca, building on collaborations in oncology and inflammatory bowel disease

Immunai, a leading AI biotech company specializing in mapping the human immune system, today announced an expansion of its collaboration with AstraZeneca, with Immunai eligible to receive up to $37.5 million over 2026-2027. The agreement extends and broadens a multi-year collaboration in oncology clinical development through 2027.

Under the expanded agreement, AstraZeneca will continue to leverage Immunai’s AMICA-OS™ AI operating system, which integrates one of the largest clinical immunology databases at single-cell resolution with advanced foundation AI models of the immune system. The platform is designed to generate clinically relevant insights across oncology drug development, including biomarker discovery, patient stratification, mechanism of action analysis, and dose optimization.

This expansion builds on previous collaborations between the two companies, including an agreement to apply Immunai’s platform across AstraZeneca oncology clinical programs in 2024 and an agreement to expand into inflammatory bowel disease in 2025.

“Across AstraZeneca, we are continuously investing in frontier AI models and solutions to inform clinical development decisions and derive novel mechanistically informed biomarkers,” said Jorge Reis-Filho, Chief of AI for Science Innovation at AstraZeneca. “The expansion of this ongoing collaboration is a reflection of our conviction in the transformative potential of AI to improve patient outcomes.”

“The fact that AstraZeneca continues to deepen this collaboration is a strong signal for us that the platform is delivering,” said Noam Solomon, Ph.D., CEO of Immunai. “We are focused on generating insights that are mechanistically grounded and clinically relevant, and collaborations like this one are how we get there.”

Immunai uses single-cell genomics and machine learning to decode the human immune system and improve the development of novel therapeutics. The company’s AMICA-OS™ AI operating system integrates large-scale immune data with foundation models to generate mechanistic and clinically relevant insights. With a team of over 170 experts, the company collaborates with leading pharmaceutical firms and academic institutions. Immunai is headquartered in New York City and has raised close to $270 million in funding to date.

Credit: Gil Kovalchuk